Monoclonal antibodies specifically targeting cd177 and related uses thereof
By developing a monoclonal antibody that specifically targets CD177, the problems of insufficient specificity and limited affinity of existing antibodies have been solved, achieving highly sensitive CD177 detection and supporting early disease diagnosis and the development of therapeutic antibodies.
CN122255281APending Publication Date: 2026-06-23HEZE SHILI HOSPITAL
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- HEZE SHILI HOSPITAL
- Filing Date
- 2026-05-13
- Publication Date
- 2026-06-23
Smart Images
Figure CN122255281A_ABST
Abstract
The application discloses a monoclonal antibody specifically targeting CD177 and related uses thereof, the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 in the heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO: 6-8, the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 in the light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO: 9-11, the monoclonal antibody has high affinity and specificity to CD177, can be used in the development of a high-sensitivity detection kit, helps early diagnosis of blood system diseases and autoimmune diseases, provides a reliable tool for CD177 pathological mechanism research, can lay an epitope foundation for subsequent development of therapeutic antibodies, and has outstanding clinical application value and scientific research conversion potential.
Need to check novelty before this filing date? Find Prior Art